WEBULL
WebtradeDownload

Did First RASONQUE (daraxonrasib) Approval and NEJM Data Just Shift Revolution Medicines' (RVMD) Investment Narrative?

Simply Wall St · 1d ago
  • Revolution Medicines has already secured US FDA approval for RASONQUE (daraxonrasib) in previously treated metastatic pancreatic adenocarcinoma and reported peer‑reviewed Phase 1/2 data in The New England Journal of Medicine for RASONQUE in RAS mutant non‑small cell lung cancer.
  • Together, these events give the company its first commercial product in a difficult cancer setting while externally validating a potential second major indication for the same medicine.
  • Now we’ll explore how RASONQUE’s first commercial approval, supported by NEJM‑published lung cancer data, may reshape Revolution Medicines’ investment narrative.

AI is about to change healthcare. These 37 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

Revolution Medicines Investment Narrative Recap

To own Revolution Medicines, you have to believe RASONQUE can anchor a meaningful franchise in RAS‑driven cancers while the company manages heavy ongoing cash burn. The first FDA approval in metastatic pancreatic cancer and NEJM‑published lung data heighten focus on the RASolve 301 and broader registrational program as near term value drivers, but they also sharpen the key risk that high spending and any clinical setbacks could leave the current valuation exposed.

Among recent announcements, the large long term headquarters leases in Redwood City stand out. They underline how far Revolution is leaning into a full scale commercial footprint just as RASONQUE transitions from pipeline asset to marketed product. This expansion increases fixed costs and makes the pace and breadth of RASONQUE uptake, and follow on indications, even more important as catalysts for justifying the company’s current spending and market value.

Yet investors should be aware that if revenue ramps slower than expected, this rising fixed cost base could...

Read the full narrative on Revolution Medicines (it's free!)

Revolution Medicines' narrative projects $3.4 billion revenue and $215.8 million earnings by 2029. This implies an earnings increase of about $2.0 billion from -$1.8 billion today.

Uncover how Revolution Medicines' forecasts yield a $221.90 fair value, a 6% upside to its current price.

Exploring Other Perspectives

RVMD 1-Year Stock Price Chart
RVMD 1-Year Stock Price Chart

Before this approval, the most cautious analysts were assuming about US$838.8 million of revenue and US$158.7 million of earnings by 2029, so their far more conservative view of RAS(ON) adoption and profitability could shift meaningfully as new pancreatic and lung cancer data challenge those earlier assumptions.

Explore 5 other fair value estimates on Revolution Medicines - why the stock might be worth over 4x more than the current price!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

Contemplating Other Strategies?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.